Tealwood Asset Management Inc. lowered its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 8.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,245 shares of the company’s stock after selling 2,955 shares during the period. Merck & Co., Inc. comprises approximately 1.3% of Tealwood Asset Management Inc.’s holdings, making the stock its 14th largest position. Tealwood Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $3,108,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in Merck & Co., Inc. by 4.6% during the third quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock worth $8,608,914,000 after purchasing an additional 3,327,404 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Merck & Co., Inc. by 11,876.3% in the third quarter. International Assets Investment Management LLC now owns 2,971,554 shares of the company’s stock valued at $337,450,000 after buying an additional 2,946,742 shares in the last quarter. Two Sigma Advisers LP raised its stake in shares of Merck & Co., Inc. by 157.9% during the 3rd quarter. Two Sigma Advisers LP now owns 4,264,100 shares of the company’s stock worth $484,231,000 after buying an additional 2,610,800 shares during the last quarter. Wulff Hansen & CO. boosted its position in shares of Merck & Co., Inc. by 11,860.9% in the 2nd quarter. Wulff Hansen & CO. now owns 2,494,199 shares of the company’s stock worth $308,782,000 after buying an additional 2,473,346 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its stake in Merck & Co., Inc. by 68.7% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 5,388,551 shares of the company’s stock valued at $611,924,000 after acquiring an additional 2,194,463 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.
Merck & Co., Inc. Price Performance
Merck & Co., Inc. stock opened at $100.94 on Tuesday. Merck & Co., Inc. has a 1 year low of $94.48 and a 1 year high of $134.63. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The firm has a 50 day moving average price of $100.16 and a 200 day moving average price of $110.36. The company has a market cap of $255.34 billion, a price-to-earnings ratio of 21.16, a PEG ratio of 1.47 and a beta of 0.39.
Merck & Co., Inc. Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 8th. Stockholders of record on Monday, December 16th were paid a $0.81 dividend. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.77. This represents a $3.24 annualized dividend and a dividend yield of 3.21%. The ex-dividend date of this dividend was Monday, December 16th. Merck & Co., Inc.’s payout ratio is currently 67.92%.
Wall Street Analyst Weigh In
MRK has been the subject of a number of research reports. Barclays cut their target price on shares of Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday, October 7th. Wells Fargo & Company reduced their target price on Merck & Co., Inc. from $125.00 to $110.00 and set an “equal weight” rating on the stock in a research note on Friday, November 1st. Daiwa America downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 11th. UBS Group cut their price target on Merck & Co., Inc. from $125.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Finally, Truist Financial reaffirmed a “hold” rating and set a $110.00 price objective (down previously from $130.00) on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $123.67.
View Our Latest Stock Report on Merck & Co., Inc.
About Merck & Co., Inc.
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- What is the Dogs of the Dow Strategy? Overview and Examples
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- What is the FTSE 100 index?
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- Basic Materials Stocks Investing
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.